Clinical Trial Update: A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer. [Phase 1]

View source ↗

Summary

A Phase 1 pilot trial evaluating NY-ESO-1b peptide with CpG 7909 and Montanide ISA-51 in cancer patients; completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• CPG 7909 (CpG 7909)
• Montanide ISA-51 (adjuvant Montanide ISA-51)
• NY-ESO-1b peptide (NY-ESO-1b peptide)

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Cancer, Neoplasm | Phase 1 | Status: COMPLETED | Results posted: 2021-07-15